Optimi Health Corp. IPO: The "Shroom Boom" Goes to Wall Street

Have you heard about using psychedelics to treat mental health? A Canadian company called Optimi Health Corp. is launching its US public stock offering (IPO). Let’s break down what they do, how they differ from the competition, and what this means for you as a potential investor.

1. What do they actually do?

Think of Optimi as a licensed drug factory based in British Columbia, Canada. They grow medical-grade magic mushrooms (psilocybin) and manufacture medical-grade MDMA.

To keep things focused, they recently shut down their side business of selling everyday, over-the-counter mushroom supplements. This strategic move lets them focus 100% of their energy and resources on the highly regulated, medical-grade psychedelics market.

2. How do they make money right now?

Unlike many of their rivals who are still stuck in the research lab phase, Optimi is actually shipping real products to global markets.

• Global Supply: They sell MDMA and psilocybin directly to clinical researchers and psychiatrists. Currently, they ship to Canada, Israel, and Australia, where doctors can legally prescribe these substances for severe depression and PTSD.
• The Reality Check: While they have a real product, sales are still very small. For the year ending September 30, 2025, Optimi brought in just US$306,000 in sales while losing US$2.7 million. In fact, they recorded zero sales in the final three months of 2025. Over their lifetime, they have lost more than US$20 million and rely heavily on outside cash to keep the lights on.

3. The Big News: Nasdaq & The Stock Split

Optimi is listing on the Nasdaq under the ticker "OPTH" at an expected price of US$6.25 per share. Here is what you need to know about the mechanics of this listing:

• The "Reverse Split": To meet Nasdaq’s minimum share price rules, Optimi recently executed a 1-for-30 reverse stock split. Think of this like trading thirty $1 bills for one $30 bill. The company's overall value didn't change, but the price per share looks much higher and more attractive to institutional investors.
• The Cash Raise: Optimi hopes to raise US$15 million by selling new shares in this IPO. After paying investment bankers and legal fees, they expect to pocket about US$12.2 million.
• The 12-Month Clock: The company estimates this new cash will only last them about 12 months. Because they don't expect to generate US sales anytime soon (entering the US market requires incredibly expensive FDA trials and DEA approvals), they will almost certainly need to issue and sell more shares in the future. This will likely dilute the value of the shares you buy today.

4. What are the main risks?

Investing in early-stage biotech is always risky, but Optimi has a few specific hurdles:

• A Serious Cash Squeeze: Optimi is running dangerously low on cash. In late 2025, they had only C$1.1 million in cash and short-term assets, but owed C$9 million in short-term bills coming due. This leaves them with a C$7.9 million shortfall. They desperately need this IPO money just to pay off immediate debts and survive.
• Heavy Government Control: Because they deal with controlled substances, Optimi needs strict federal licenses for everything they do. They must secure individual government permits for every single export shipment. Furthermore, the US DEA sets strict annual limits on how much of these substances can enter the country. If regulators delay a permit, business grinds to a halt.
• Public Perception: Psychedelics are still highly controversial. Any bad press, political pushback, or negative patient experiences in clinical trials could quickly scare doctors and patients away from these treatments.
• Recalls and Competition: If a batch of their medical mushrooms is contaminated, a product recall could ruin their reputation and drain their remaining cash. At the same time, they are competing against massive pharmaceutical companies with significantly deeper pockets.

The Bottom Line: Is Optimi Right for You?

Optimi is a unique player in the psychedelic space because they are actually producing and shipping physical products today, rather than just promising future discoveries.

However, they are currently losing money, facing a tight C$7.9 million cash crunch, and are entirely dependent on unpredictable government approvals.

Before you buy, ask yourself: Are you comfortable with high-risk, high-reward biotech stocks? Can you handle the likelihood of future share dilution as they raise more money to fund FDA trials? If you have a high risk tolerance and believe in the long-term future of psychedelic medicine, Optimi (OPTH) is definitely an interesting, pioneering stock to keep on your radar.